patient stratification

AltraBio is a contract research company specializing in advanced biological data analysis and bioinformatics services, helping biopharma, cosmetic, and clinical R&D organizations extract insights from cytometry, omics, and medical data using AI, machine learning, and biostatistics. It serves pharmaceutical companies, biotech startups, dermo-cosmetic leaders, and university hospitals worldwide.

automated gatingbioinformatics pipeline developmentbiomarker discoverybiostatisticsbulk transcriptomicscytometry data analysishigh-dimensional panel analysismachine learningproteomicsreal-world data miningsingle-cell RNA-seq analysisstatistical modelingtarget identification

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) uses explainable AI and machine learning to accelerate drug discovery and development for biopharma teams. Its platform combines biology-aware data harmonization, Causal AI analytics, and structured, auditable decision support to turn multi-omic and clinical data into patient subgroups, translational signals, and candidate rankings. bfLEAP® was developed in partnership with Johns Hopkins University Applied Physics Laboratory, and its neuroscience data infrastructure is built with the Lieber Institute for Brain De

Causal AI analyticsdata harmonizationdecision supportdrug target discoveryexplainable AImachine learningpatient subgroup discovery

Foli Bio is building a molecular data layer for gut biology through stool-derived host RNA. Its Foli-seq™ platform profiles host RNA from naturally shed gut epithelial and immune cells to reveal mucosal inflammation, barrier function, disease biology, and therapeutic response, enabling non-invasive longitudinal transcriptomic readouts for translational studies, biomarker discovery, clinical diagnostics, and precision medicine.

assay developmentbiomarker discoveryhost gut transcriptomicsNGS bioinformaticspharmacodynamic monitoringstool-derived host RNA profiling

Gutz Analytics builds AI models to better understand human disease through subtyping, aiming to lower patient care costs and enable effective treatments. Its Dynomics platform uses Dynamic Variational Autoencoders (DVAE) to create digital twins from multi-omics data, identifying disease subtypes that predict treatment response. The company's current focus is autism spectrum disorder, with applications in oncology, autoimmune diseases, and neurological conditions.

AI/machine learning modelingBioinformaticsdigital twinsdisease subtypingDynamic Variational Autoencoders (DVAE)multi-omics data integration

From multi-omics complexity to translational insights We integrate deep immune profiling with AI-powered translational insights to reveal the mechanisms underlying health, disease and therapeutic response.Start a collaboration IMMUNASYST provides computational deep immune profiling of health and disease through multi-omics integration, combining mechanistic systems IMMUNology with the SYSTematic orchestration of intelligent AI agents - like a coordinated immune response.Our specialization runs through infectious disease, oncology, and autoimmunity — yet systems biology honors no boundaries, reaching across virtually any condition where mechanism matters.The work is collaborative by design. You bring the disease area, cohort, and clinical context. We bring systems immunology, rigorous statistics, and AI-enabled translational analysis to turn complex data into mechanistically grounded.

AI-enabled translational analysisATAC-seqbiomarker discoveryclinical trial designFlow Cytometrymanuscript writing supportmetabolomicsmicrobiome analysismulti-omics integrationproteomicsspatial omicssystems immunologytranscriptomics